It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

Boehringer Ingelheim reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion.

IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for ...

It’s a sentiment felt widely across the medical field as AI starts to touch nearly every corner of medical research, physician training and processes, and patient care. The rollout of AI across health ...

Management of chronic thromboembolic pulmonary hypertension (CTEPH) includes multimodal therapy that depends on expert ...

Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an ...

01.01.01-00-0382/16). Despite various treatments, the first-line approach for rheumatoid arthritis (RA) has long relied on ...